By Billy Candra 
A groundbreaking pan-Canadian initiative has unveiled a revolutionary method to expedite the identification of personalized treatments for young cancer patients, leveraging an innovative approach that involves cultivating their tumours in chicken eggs and meticulously analyzing their protein profiles. This pioneering work, a testament to interdisciplinary collaboration, marks a significant leap forward in precision oncology, offering a beacon of hope for children battling aggressive and treatment-resistant cancers.
The team, spearheaded by researchers from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), has achieved a Canadian first by successfully integrating these two sophisticated techniques. This synergistic combination allowed them to identify and rigorously test a specific drug for a young patient’s tumour within a timeframe critical for their ongoing treatment. Their remarkable success in pinpointing an effective new therapeutic strategy for a patient, detailed in the prestigious journal EMBO Molecular Medicine, underscores the immense value of proteomics—the comprehensive study of proteins—as a vital complement to the well-established field of genomics (the study of genes) in the context of real-time cancer therapies. This advancement highlights a paradigm shift, moving beyond genetic predispositions to target the functional machinery of cancer cells.
The Unrelenting Challenge of Pediatric Cancer
Pediatric cancer remains a formidable adversary in medicine, presenting unique challenges distinct from adult malignancies. Unlike adult cancers, which are often linked to lifestyle factors and environmental exposures, childhood cancers frequently arise from random genetic mutations or developmental anomalies, making their prevention incredibly difficult. Globally, cancer is a leading cause of death by disease among children and adolescents, with an estimated 400,000 children and adolescents (0-19 years old) diagnosed with cancer each year. In Canada, approximately 1,000 children are diagnosed with cancer annually. While survival rates for some pediatric cancers have dramatically improved over decades, reaching over 80% for certain types, others, particularly rare or aggressive forms, continue to have grim prognoses.
A significant hurdle lies in the fact that many conventional cancer treatments, such as chemotherapy and radiation, were originally developed for adults. These treatments, while effective, can have devastating long-term side effects on a child’s developing body, including secondary cancers, organ damage, and cognitive impairments. Furthermore, for a subset of pediatric patients, particularly those with rare or relapsed cancers, standard therapies prove ineffective, and their tumours develop resistance, leaving few, if any, viable treatment options. This critical unmet need has spurred researchers worldwide to explore more precise, less toxic, and highly individualized therapeutic strategies. The case of the unnamed patient in this study perfectly exemplifies this dire scenario, where conventional treatments had failed, and the tumour proved stubbornly resistant.
Genomics: A Foundation with Evolving Limits
In recent years, genomic sequencing has revolutionized cancer care, offering unprecedented insights into the genetic mutations driving individual tumours. By mapping a tumour’s genetic blueprint, oncologists can often identify specific mutations that can be targeted by precision drugs, ushering in the era of personalized medicine. For many patients, genomic profiling has led to life-saving treatments, guiding clinicians to therapies that are more effective and less harmful than broad-spectrum chemotherapy.
However, genomics, while powerful, is not without its limitations, especially in complex and treatment-resistant cases. Genes provide the instructions for making proteins, but it is the proteins themselves that perform the vast majority of functions within a cell. A genetic mutation may or may not translate into a functional change at the protein level, or the cellular machinery might adapt in ways that bypass the targeted genetic pathway. In some instances, genomic analysis may fail to identify clear, actionable targets, or a tumour may develop resistance to a genetically guided therapy, as observed in the patient central to this study. After standard chemotherapy had failed and the tumour became resistant to a drug initially selected based on genomic insights, further genetic testing yielded no clear alternative drug candidates. This impasse underscored the necessity for a complementary approach, one that could probe deeper into the tumour’s actual functional state.
Proteomics: Unlocking the Functional Blueprint of Cancer
It was at this critical juncture that the pan-Canadian team turned its attention to proteomics. While genes carry the instructions, proteins are the functional workhorses of the cell, carrying out virtually all cellular processes, from metabolism and signaling to structural support. Crucially, most drugs exert their therapeutic effects by directly interacting with and altering the activity of proteins. The team hypothesized that by studying the tumour’s protein landscape, they could uncover "hidden weaknesses" or vulnerabilities that genetic testing alone might miss, especially when a tumour has developed complex resistance mechanisms.
Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, served as co-lead authors on the study. Their meticulous proteomic analysis of the patient’s tumour yielded a breakthrough discovery: the tumour’s metabolism was heavily reliant on an enzyme known as SHMT2 (Serine Hydroxymethyltransferase 2). This enzyme plays a crucial role in one-carbon metabolism, a fundamental pathway for cell growth and proliferation, particularly in rapidly dividing cancer cells.
"With genomics alone, we couldn’t find a clear treatment option," stated Dr. Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, alongside Dr. Lim and clinician Dr. Rebecca Deyell. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug." This discovery was significant because SHMT2 represented a metabolic choke point, a vulnerability that, if exploited, could starve the tumour of essential resources for growth. The researchers’ innovative strategy involved repurposing sertraline, a widely available and commonly prescribed antidepressant, which they identified as an inhibitor of SHMT2. By inhibiting SHMT2, sertraline could effectively cut off the tumour’s access to a key energy source, thereby impeding its growth.
The Chicken Egg Avatar: A Rapid Testbed for Personalized Therapy
Identifying a potential drug candidate is only one part of the equation; validating its efficacy for an individual patient’s tumour is the next, often time-consuming, step. Traditional methods, such as patient-derived xenografts (PDX) in mice, can take months, a luxury often unavailable for children with aggressive, rapidly progressing cancers. To overcome this critical time constraint, the team employed a cutting-edge method involving the growth of a small piece of the patient’s tumour on a fertilized chicken egg.
This technique utilizes the chorionic allantoic membrane (CAM) of a developing chicken embryo, which provides a rich vascularized environment capable of supporting tumour growth. Essentially, the chicken egg serves as a living "avatar host" for the patient’s tumour. Growing an identical tumour outside the patient offered an unprecedented opportunity to test for personalized drug responses in a matter of weeks, rather than months. The ethical considerations are also noteworthy; using chicken eggs for this purpose is generally considered less ethically complex than using live mammalian models, while still providing a highly relevant biological environment.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," explained Dr. Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour." This rapid turnaround time is paramount in pediatric oncology, where swift decision-making can directly impact a child’s prognosis. The chicken egg avatars are a key component of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, a program specifically designed to bridge the gap between clinical needs and research laboratory capabilities within the hospital. This initiative embodies a commitment to accelerating the translation of scientific discoveries into tangible patient benefits.
A Collaborative Triumph: The Role of PROFYLE and ACCESS
This scientific breakthrough is not merely the result of individual brilliance but a powerful demonstration of collaborative synergy facilitated by national networks. The work was a cornerstone effort of PROFYLE (PRecision Oncology For Young peopLE), a flagship initiative of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). PROFYLE represents an unprecedented collaborative ecosystem, bringing together over 30 research and funding organizations and more than 100 investigators from across Canada. Its overarching mission is to enhance cancer outcomes for children and young adults by accelerating access to precision oncology.
When the team identified sertraline as a potential treatment, their findings were presented to a panel of experts established by PROFYLE. This multidisciplinary panel, comprising oncologists, pathologists, geneticists, and pharmacologists from various institutions, rigorously reviewed the evidence derived from both genomics and proteomics, as well as the efficacy data from the chicken egg avatar model. After careful consideration, the panel endorsed sertraline as the most promising treatment option available for the patient at that critical juncture, underscoring the trust placed in this novel diagnostic and testing pathway. This collaborative review process ensures that decisions are robust, evidence-based, and benefit from the collective wisdom of Canada’s leading pediatric cancer specialists.
Encouraging Results and the Road Ahead
Following the expert panel’s recommendation, the patient began treatment with sertraline. The results, while not a complete cure, were unequivocally encouraging. The patient’s tumour growth slowed significantly, providing a crucial window for further intervention and improved quality of life. This partial response, in a case where all conventional treatments had failed, offers profound validation for the integrated proteomics and avatar testing approach. It demonstrates that this method can indeed deliver personalized treatment recommendations rapidly enough to provide tangible benefits to patients grappling with rare and notoriously difficult-to-treat cancers.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," affirmed Dr. Lange. "We now hope to expand this method to other children to identify effective treatments faster across the country."
The implications of this research extend far beyond this single patient’s case. It offers a blueprint for the future of personalized oncology, particularly for patient populations where conventional approaches fall short. The ability to rapidly identify actionable protein targets and validate drug efficacy in an avatar model presents several transformative possibilities:
- Accelerated Drug Discovery and Repurposing: The methodology could significantly accelerate the discovery of new therapeutic targets and, crucially, the repurposing of existing, approved drugs for novel cancer indications, reducing the lengthy and expensive drug development pipeline.
- Broader Applicability: While demonstrated in a rare pediatric cancer, the principles of integrating proteomics and avatar testing could be applied to a wider spectrum of cancers, both in children and adults, especially those that are refractory to standard therapies.
- Improved Patient Outcomes: By providing clinicians with personalized, evidence-based treatment options in a timely manner, this approach has the potential to improve survival rates and reduce the long-term toxicity associated with empirical, broad-spectrum treatments.
- Enhanced Understanding of Resistance Mechanisms: The detailed proteomic analysis offers deeper insights into how tumours develop resistance, paving the way for the development of strategies to overcome these challenges.
- Ethical and Economic Advantages: The use of chicken egg avatars offers an ethical and cost-effective alternative to traditional animal models, making personalized drug testing more accessible.
However, the researchers acknowledge that further work is essential. This includes validating the approach in larger cohorts of pediatric cancer patients, establishing standardized protocols for its widespread implementation, and navigating the regulatory pathways for integrating such novel diagnostic and treatment selection tools into routine clinical practice. Funding will also be critical to scale this pan-Canadian effort and ensure equitable access for all eligible children.
This seminal work from the University of British Columbia, BC Children’s Hospital Research Institute, and the PROFYLE/ACCESS networks represents a monumental step forward in the fight against pediatric cancer. By marrying sophisticated proteomic analysis with rapid, personalized drug testing using chicken egg avatars, Canadian researchers have forged a powerful new weapon in the arsenal against this devastating disease, offering renewed hope and tangible progress for young patients and their families across the nation and potentially, worldwide. The journey to a cure is ongoing, but this breakthrough illuminates a promising new path towards truly individualized and effective cancer care.
